33-health-recovery

The Alchemy Probability Data sub-project is the computational substrate that powers every disease-cure discovery in this bundle. It is a Python-based probability engine built on the proprietary Alchemy Data V2 system. Core scripts include alchemy_config.py (configuration and element definitions), alchemy_data_v2.py (the probability-calculation engine that computes discovery scores and degree-based probability cascades through 240th-degree resolution), bluray_data_api.py (data-access layer), and bluray_data_generator.py (archival output generator). The database stores elemental probability matrices, transformation pathways (heat, mix, oxidation, synthesis, phase-change, ionization, alloy-formation reactions with exact temperature, catalyst, environment, energy-change, and probability values), and synthesis methods for every candidate compound. Each compound receives a discovery score out of 100 based on its mechanism coverage, probability ranking, and transformation richness. Four blueprint documents (commons.odf, abnormal.odf, reallight.odf, unique.odf) define the foundational element relationships. This engine is the shared analytical backbone of sub-projects 3, 4, 5, 6, and 7.

A comprehensive cure-focused database search conducted on January 12, 2026, using the Alchemy Data V2 system. The search identified 11 cure-focused compounds across 9 distinct cure mechanisms. The top candidate, C-H-O-N, achieved a discovery score of 50.5 / 100 with a probability of 0.010094.

The 9 identified mechanisms: cell regeneration (11 compounds); beta cell regeneration (11 compounds); insulin regeneration (11 compounds); growth factors (11 compounds); glucose metabolism restoration (10 compounds); insulin signaling pathway activation (8 compounds); glycogen synthesis (2 compounds); insulin sensitivity improvement (2 compounds).

Deliverables include the full compound discovery JSON (with probability cascades through 240th degree, transformation matrices, and synthesis methods for each compound), known-properties reports (three versions), a patent application draft, four SVG patent drawings (chemical structures, synthesis scheme, coordination structures, pharmaceutical formulations), reference charts, and the Python discovery engine (run_diabetes_discovery.py, config.py).

A parallel cure-focused database search targeting Alzheimer’s disease mechanisms. The research identified candidate compounds scored against mechanisms including neuroinflammation, BDNF signaling, synaptic function, neuronal regeneration, tau regulation, antioxidant activity, amyloid reduction, cholinergic support, mitochondrial function, glutamate regulation, and calcium homeostasis.

The patent application (USPTO 19/441,975), titled “Novel Metal-Amino Acid Complexes and Methods for Treating Alzheimer’s Disease,” contains 20 claims: 4 independent claims covering zinc-amino acid coordination complexes (broadest amyloid + tau coverage), copper-amino acid coordination complexes (amyloid clearance + antioxidant), multi-metal coordination complexes (Fe-S, Fe, Fe-Cu for mitochondrial support), and mineral-enhanced complexes (Mg, Ca for neuroprotection); plus 16 dependent claims covering amino acid specificity (histidine, cysteine/methionine, glycine/glutamic acid), pharmaceutical compositions (oral, injectable, intranasal), methods of treatment, and synthesis methods. The package includes four SVG patent drawings and the full discovery data with compound-level probability matrices.

Filed January 12, 2026 (Confirmation No. 4455, Patent Center No. 73928275). The application is titled “Novel Metal-Amino Acid Complexes and Methods for Treating Parkinson’s Disease.”

The patent contains 20 claims organized as follows:

Total compound coverage: 12 compound types (4 halogen, 3 boron/silicon, 3 multi-metal, 2 complex hybrids). Deliverables include the full patent specification (DOCX), four SVG patent drawings, USPTO forms, the filing receipt, and the complete discovery data JSON.

A comprehensive database covering 300 non-opioid diseases, each with a dedicated cure-research document generated from the Alchemy Data V2 engine. Of the 300 cures analyzed, 223 (74.3%) are classified as novel (new alchemy-based compounds not found in standard pharmaceutical databases), and 77 (25.7%) are hybrid (combining established and novel approaches). All 300 contain novel elements.

The database is backed by a large Python analysis pipeline (30+ scripts) including generate_cures.py, deep_alchemy_analysis.py, discover_medical_compounds.py, cross_search_drug_studies.py, extract_alchemy_compounds.py, categorize_treatments.py, add_probability_matrices.py, add_transformation_pathways.py, and others. Supporting data files include alchemy_compounds.json, real_alchemy_data.json, FOUR_DATABASE_EXAMS_REPORT.json, DEEP_ALCHEMY_ANALYSIS.json, and MEDICAL_COMPOUND_DISCOVERY_REPORT.json.

A patent-pending, computationally designed 7-compound brain-optimization formulation. Designed using a proprietary algorithmic method that analyzed 54 brain diseases, 65 neurotransmitters, and 40 neurobiochemical mechanisms. The formulation delivers 10 of 14 brain-essential chemical elements (C, H, O, N, Mg, Zn, Se, P, Fe, S) through bioavailable, blood-brain-barrier-crossing forms. Elements not covered: Cu, I, Mn, Cl (addressed in patent claims as optional additions). The global brain health supplement market is valued at approximately $14 billion (2026).

Daily total: 2,665 mg across 3 capsules (1 morning, 2 evening; Size 00 HPMC vegetarian capsules).

Dosing schedule rationale: Iron bisglycinate (AM) and NAC (PM) are separated by 12 hours to prevent thiol chelation of Fe²⁺. P5P supports active-phase neurotransmitter synthesis during waking hours. Ebselen and NAC support glutathione regeneration during sleep-phase neurochemistry. Magnesium L-threonate is split AM/PM for steady-state brain magnesium levels.

Morning capsule (Capsule A, 960 mg fill): Magnesium L-threonate 500 mg, Zinc carnosine 75 mg, P5P 25 mg, Iron bisglycinate 25 mg, Citicoline 250 mg, excipients (MCC, Mg stearate, SiO₂) 85 mg.

Evening capsule B1 (830 mg fill): Magnesium L-threonate 500 mg, Ebselen 300 mg, excipients 30 mg.

Evening capsule B2 (880 mg fill): N-Acetyl-L-Cysteine 600 mg, Citicoline 250 mg, excipients 30 mg.

Patent application 19/555,525 (filed March 3, 2026; Confirmation No. 9226) contains 24 claims:

Supporting deliverables include 9 SVG patent drawings, the complete brain diseases database (54 diseases), neurotransmitter database (65 neurotransmitters), brain elements database (20 elements), Python research tools (brain_chemistry_db.py, brain_compound_analyzer.py, neurotransmitter_db.py, supplement_facts.py, report_generator.py), a product valuation report, test suites, and a research-document library.

FDA disclaimer: The OTC vitamin formulations and the NeuroElement supplement described in this package have not been evaluated by the U.S. Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. The disease-cure research (diabetes, Alzheimer’s, Parkinson’s, 300-disease database) consists of computational research findings that have not been clinically validated. No compound discussed in this package is a proven treatment or cure for any disease. Nothing in this package constitutes medical advice. Consult a qualified health professional before using any supplement or acting on any research finding contained herein.

Intellectual property note: Three sub-projects carry active USPTO patent applications (19/441,975, 19/445,644, 19/555,525). This is a single-tier purchase. Intellectual property is not conveyed with purchase; IP-related terms require separate negotiation.

This package ships on a single Blu-ray disc, posted to the delivery address on your order. The archive on the disc is AES-256 encrypted; the passphrase is sent separately, by email, once the disc is despatched — so the disc alone is of no use to anyone who intercepts it.

Discs are despatched by tracked, signed-for post. Allow 5 business days for mastering and verification before despatch.